Standard of Care sensibility: Anti-PD1 = yes / Anti PDL1 = yes (12,5 mg/kg)
Acquired resistance to: PD1/PDL1
Tyr-Nras cells
Mouse Tyr-Nras cells were isolated from a primary melanoma of a C57BL/6 mouse. They were authenticated by Microsynth.
Tumour growth in vivo
Tumor fragments were collected from an in vivo tumor and surgically implanted subcutaneously in the right flank of C57BL/6 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing Tyr-Nras tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the Tyr-Nras cells as subcutaneous tumours
Mean ± SEM (n=6; take rate 100%)
Drug Responses
Anti-PD1 12.5 mg/kg → Response
Anti-PDL1 12.5 mg/kg → Response
Immunophenotyping data of the lymphoid and myeloid lineage are available upon request.
Antineo has developed models of secondary resistance to anti-PD1 or anti-PDL1 (ID Tyr-Nras anti PD1R and Tyr-Nras anti-PDL1R). These models have been developed in vivo without genetic modifications.